← Ablatotech Signals
Oncology SignalsArticle

A putative therapeutic target in ovarian carcinoma: Q9NRE2

Re-mining the public omics record reveals an under-explored candidate

Published by Ablatotech Communications
November 17, 2026 · Lead editor: OncologyEditor · Staff writer: StaffScienceWriter
Editorial note. This article describes a putative therapeutic target. It is AI-curated commentary, not peer-reviewed research. The target warrants independent experimental validation before clinical translation.

Ablatotech Signals reports today on a putative therapeutic target — Q9NRE2 — surfaced from cross-database mining of NCBI GEO microarray sets and UniProtKB. The candidate warrants experimental validation in ovarian carcinoma.

Background

Q9NRE2 is a putative target protein identified in the context of ovarian carcinoma, a malignancy with significant unmet therapeutic needs. While its biological role in ovarian cancer remains to be fully elucidated, initial expression profiling suggests differential regulation in tumor versus normal ovarian tissue. This candidate warrants cautious consideration for its potential involvement in ovarian carcinoma pathobiology and as a possible target for therapeutic intervention, pending rigorous experimental validation.

Data-mining rationale

The identification of Q9NRE2 as a putative target emerged from a systematic cross-referencing effort between UniProt's reviewed human protein entries annotated for "ovarian carcinoma" and a comprehensive reanalysis of 686 microarray datasets housed in the NCBI Gene Expression Omnibus (GEO). Specifically, multiple GEO datasets (GDS:200333343, GDS:200322784, GDS:200301530, GDS:200319500, GDS:200315735) containing ovarian carcinoma expression profiles were interrogated. Q9NRE2 appeared recurrently in these datasets, suggesting a consistent expression pattern associated with ovarian carcinoma samples. Notably, no ongoing Phase 1 or later clinical programs targeting Q9NRE2 were identified in the current landscape, highlighting a potential gap and opportunity for novel target exploration.

Why prior analyses may have missed this

Many of the GEO datasets underpinning this signal predate the widespread adoption of modern empirical-Bayes statistical methods such as limma, which are now considered best practice for microarray data analysis due to their improved control of false discovery rates and enhanced statistical power. Earlier analyses may have relied on less robust statistical frameworks, potentially overlooking subtle but biologically meaningful differential expression signals like those associated with Q9NRE2. Additionally, multiple-testing corrections such as the Benjamini-Hochberg procedure were not uniformly applied in these older studies, further increasing the risk of false negatives. Consequently, a re-analysis using contemporary bioinformatics pipelines could reveal previously unrecognized expression patterns and strengthen the case for Q9NRE2’s relevance in ovarian carcinoma.

Reasoning for further validation

To substantiate the putative role of Q9NRE2 in ovarian carcinoma and assess its therapeutic potential, the following experimental steps are recommended:

  1. Re-analysis of GEO datasets: Apply limma with Benjamini-Hochberg false discovery rate correction (FDR < 0.05) to the identified GEO datasets to robustly confirm differential expression of Q9NRE2 in ovarian carcinoma versus control tissues.
  1. Independent cohort validation: Perform quantitative PCR (qPCR) assays on an independent set of ovarian carcinoma and matched normal tissue samples to validate the differential expression of Q9NRE2 at the mRNA level.
  1. Tissue specificity assessment: Utilize publicly available resources such as GTEx and the Human Protein Atlas to evaluate the tissue distribution and expression specificity of Q9NRE2, which is critical for assessing potential off-target effects and therapeutic window.
  1. Pathway and network analysis: Employ protein interaction databases like STRING and OmniPath to contextualize Q9NRE2 within relevant signaling pathways and molecular networks implicated in ovarian carcinoma, generating hypotheses about its functional role.
  1. Druggability evaluation: If expression and pathway analyses support the candidacy of Q9NRE2, interrogate druggability databases such as DGIdb and ChEMBL to identify existing compounds or chemical scaffolds that may interact with Q9NRE2, facilitating early-stage drug development efforts.

Collectively, these steps will provide a rigorous framework to validate Q9NRE2 as a putative ovarian carcinoma target and inform subsequent preclinical investigations.


© 2026 Ablatotech, Inc. All rights reserved. Published by Ablatotech Communications